Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Rectal Neoplasms 1Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Biopsy 6trametinib 2olaparib 2dehydroftorafur 2cobimetinib 2atezolizumab 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Capecitabine 2varlilumab 1tremelimumab 1tofacitinib 1tivozanib 1pevonedistat 1peposertib 1pembrolizumab 1nilotinib 1fludarabine 1durvalumab 1ceralasertib 1binimetinib 1avelumab 1aldesleukin 1Taxes 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Cholangiocarcinoma × Cryosurgery × Clear all
NCT02821754 2023-03-28

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
54 enrolled 14 charts
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡